1stOncology™: Cancer Intelligence Service – Page 12304 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Ryvu Therapeutics to Present Recent Data From Multiple Oncology Programs at AACR 2020 Annual Meeting

On February 27, 2020 Ryvu Therapeutics (WSE: RVU), a clinical stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, reported that data from its multiple oncology programs will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place April 24 to April 29, 2020, in San Diego, CA (Press release, Ryvu Therapeutics, FEB 27, 2020, View Source [SID1234554950]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Data presented will include results from the small-molecule STING agonists, dual A2A/A2B adenosine receptors antagonist program, HPK1 inhibitors and SMARCA2 (BRM) degraders program.

Details of the poster presentations are as follows:

Title: In vivo and in vitro characterization of RVU330 best-in-class dual A2A/A2B adenosine receptor antagonist
Session Title: Immunomodulatory Agents and Interventions 2
Session Date and Time: Tuesday, April 28, 2020 1:30 PM – 5:00 PM (PST)
Location: Section 46
Poster Board Number: 15
Permanent Abstract Number: 5555

Title: Development of selective small molecule STING agonists suitable for systemic administration
Session Title: Immunomodulatory Agents and Interventions 1
Session Date and Time: Tuesday, April 28, 2020, 9:00 AM – 12:30 PM (PST)
Location: Poster Section 49
Poster Board Number: 27
Permanent Abstract Number: 4521A

Title: Development and characterization of small molecule HPK1 inhibitors
Session Title: Small Molecule Therapeutic Agents
Session Date and Time: Monday, April 27, 2020 9:00 AM – 12:30 PM (PST)
Location: Poster Section 31
Poster Board Number: 14
Permanent Abstract Number: 1947

Title: Development of novel, selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1) mutated tumors
Session Category: Molecular and Cellular Biology/Genetics
Session Title: Histone Modifications and Epigenomics
Session Date and Time: Tuesday, April 28, 2020 9:00 AM – 12:30 PM (PST)
Location: Poster Section 9
Poster Board Number: 15
Permanent Abstract Number: 3656

Presentations will be held at the San Diego Convention Center, Exhibit Halls A-F, in respective Poster Sections. Additional information is available at on the AACR (Free AACR Whitepaper) conference website View Source

Apexigen To Present At Upcoming Investor Conferences

On February 27, 2020 Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, reported that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, will present at the following upcoming investor conferences (Press release, Apexigen, FEB 27, 2020, View Source [SID1234554949]):

Cowen’s 40th Annual Healthcare Conference
Tuesday, March 3, 2020 at 11:30 am ET in Boston, MA

Solebury Trout’s Spring 2020 Private Company Showcase
Thursday, April 2, 2020 in New York, NY

Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma

On February 27, 2020 Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments, reported that the Company’s investigational CD30-directed autologous chimeric antigen receptor T cell (CD30 CAR-T) therapy has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed or refractory CD30-positive classical Hodgkin lymphoma (cHL) (Press release, Tessa Therapeutics, FEB 27, 2020, View Source [SID1234554948]). Tessa expects to initiate its pivotal Phase II multi-site trial in the fourth quarter of 2020.

"The RMAT designation speaks to the strength of the data in two independent Phase I/II trials, which show promising efficacy and a strong safety profile of the therapy in Hodgkin lymphoma patients whose disease had failed to respond to other available therapies," said Ivan D. Horak, M.D., President of Research and Development at Tessa Therapeutics. "We look forward to working closely with the FDA as we advance our trial at multiple sites in North America and work to bring this potentially transformative treatment option to patients."

The RMAT designation is supported by clinical data from two independent CD30 CAR-T Phase I/II studies in patients with relapsed or refractory CD30-positive classical Hodgkin lymphoma conducted by Baylor College of Medicine (NCT02917083) and University of North Carolina Lineberger Comprehensive Cancer Center (NCT02690545). Both studies demonstrated objective response rates of more than 70%, with 18 patients achieving complete response out of 27 patients treated with CD 30 CAR-T with lymphodepleting chemotherapy as of November 2019.

Dr Horak added: "As part of our longer-term R&D program, we are also developing an allogeneic CD30-CAR Epstein-Bar Virus-Specific T cell (CD30-CAR EBVST) therapy product that combines the unique properties of VSTs and CD30 CARs, in an effort to develop off-the-shelf cell therapies intended to treat a range of hematologic malignancies and solid tumors."

RMAT designation is designed to facilitate development and expedite review of cell therapies and other qualifying regenerative medicines intended to treat a serious or life-threatening disease or condition; and preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition. Advantages include all the benefits of the FDA’s Fast Track and Breakthrough Therapy Designation programs, such as early interactions with the FDA that may be used to discuss potential surrogate or intermediate endpoints to support accelerated approval and satisfy post-approval requirements.

Ionis Pharmaceuticals to present at upcoming investor conferences

On February 27, 2020 Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, reported that management will present a company overview at the following investor conferences (Press release, Ionis Pharmaceuticals, FEB 27, 2020, View Source [SID1234554947]):

Cowen 40th Annual Health Care Conference on Wednesday, March 4, 2020; and
Oppenheimer 30th Annual Healthcare on Wednesday, March 18, 2020.
The above listed dates are subject to change. Details on presentation times or changes to presentation dates can be found on the Company’s website. Please check www.ionispharma.com for the latest information.

A live webcast of the presentations will be available on the Investors & Media section of the Ionis website. The replays will be available within 48 hours and will be archived for a limited time.

RareCyte announces the first blood-to-result PD-L1 Circulating Tumor Cell Assay

On February 27, 2020 RareCyte reported a liquid biopsy blood test for programmed death-ligand 1 (PD-L1), enabling customers to evaluate PD-L1 expression on circulating tumor cells (CTCs) with industry leading sensitivity. PD-L1 is a biomarker that directs checkpoint inhibitor immunotherapy treatment and liquid biopsy offers a noninvasive method to evaluate biomarker expression for treatment selection and patient monitoring in clinical research (Press release, RareCyte, FEB 27, 2020, View Source [SID1234554946]).

With the RareCyte PD-L1 assay and the AccuCyte-CyteFinder system, blood from a single tube is processed to cells for CTC enumeration and PD-L1 biomarker expression analysis, and to plasma for optional cfDNA analysis. Single CTCs can also be retrieved using the CytePicker Module for sequencing analysis. As a result, the RareCyte assay provides the first comprehensive liquid biopsy solution for PD-L1 analysis.

The PD-L1 Panel Kit was validated based on rigorous requirements set to clinical standards. Tad George, PhD, SVP of Biology R&D at RareCyte noted, "Our approach to assay development and validation is centered on creating globally deployable products that combine the sensitivity, specificity, and precision required for multi-center clinical trials for CTC enumeration and phenotyping. In addition, the RareCyte platform enables cell-free DNA analysis on the same sample, providing a comprehensive assessment of patient status."

Joe Victor, CEO of RareCyte, said "We released this new assay as a response to customer feedback from an earlier generation assay still in use today and we anticipate that this PD-L1 Panel Kit will be utilized in a variety of exploratory clinical research this year." The PD-L1 Panel Kit is now available for purchase. More information on the PD-L1 Panel Kit and the RareCyte platform is available at View Source

RareCyte products are for research use only. Not for use in diagnostic procedures.